AptarGroup Q1 Sales Up 11% to $982.9M, Adjusted EPS $1.19
Net income fell to $72.7 million in Q1 on revenues of $982.9 million, while reported EPS was $1.12 and adjusted EPS was $1.19. AptarGroup expects Q2 adjusted EPS between $1.32 and $1.40 and returned $131 million to shareholders through buybacks and dividends.
1. Q1 Financial Results
AptarGroup reported first-quarter net income of $72.7 million, down 8% year-over-year, on revenues of $982.9 million, an 11% increase. Reported earnings per share were $1.12, with adjusted EPS of $1.19 versus $1.30 in the prior year, both surpassing analysts’ forecasts.
2. Segment Performance
Pharma sales rose 7% reported but core sales fell 1% due to emergency medicine destocking, while injectables grew double digits. Beauty delivered 19% reported growth (3% core), driven by fragrance dispensing, and Closures saw 5% reported gains with flat core volume amid lower resin pricing.
3. Outlook and Capital Returns
AptarGroup projects second-quarter adjusted EPS of $1.32 to $1.40, assuming a 1.18 EUR/USD rate and a 22.5%-24.5% tax rate. During Q1 the company returned $131 million through $100 million of buybacks and $31 million in dividends at $0.48 per share.
4. Leadership Update
Gael Touya will become CEO on September 1, 2026, succeeding Stephan Tanda as part of the company’s long-term succession plan.